AI Generated Image
Experimental weight loss pill doesn’t make you eat less
New York Post • • health
Key Points:
- GLP-1 drugs like Ozempic and Wegovy reduce appetite, helping many users eat less and lose weight, but some experience a loss of pleasure and satisfaction from eating.
- A new experimental compound, TOFA, has shown promise in mice by increasing metabolism and energy expenditure without reducing appetite, potentially addressing issues related to nutrient deficiencies and muscle loss seen in GLP-1 users.
- TOFA works by blocking fatty acid production in the liver and boosting energy use, improving insulin sensitivity and features of fatty liver disease without raising harmful triglyceride levels.
- Combining TOFA with GLP-1 drugs in mice resulted in better outcomes for weight loss, glucose control, insulin levels, and triglycerides than using either treatment alone.
- While results in mice are promising, TOFA’s safety and effectiveness in humans remain untested, and researchers see it as a complementary treatment to GLP-1 drugs rather than a replacement.
